HOME | INFORMATION | FORMULAS | TESTIMONIALS | QUESTIONS | NEWSLETTER | ORDER
 DO YOU NEED HELP WITH:




PATENTS ( Awarded and or Licensed to DocBlum)


The issued gene patents are owned by both the University Of Texas System and the University Of Calofornia Sytem. Intellectual Property of NUTRIGENOMICS, Inc.


NUTRIGENOMICS, Incorporated through an intellectual property license from KENNETH BLUM, Ph.D. INC. controls the following intellectual properties with the specified limitations:

RDS Gene Testing -Patent to Dr.Kenneth Blum as primary inventor

- U. S. Patent Number: 5210016     Date of Issue: May 11, 1993

ALLELIC ASSOCIATION OF THE HUMAN DOPAMINE (D2) RECEPTOR GENE IN COMPULSIVE DISORDERS SUCH AS ALCOHOLISM
The present invention concerns a method for diagnosing compulsive disease predisposition of an individual. The method comprises initially obtaining a DNA sample of said individual and then determining the presence or absence of a particular human D2 receptor gene allele in said sample. Detection of said allele in the sample is indicative of predilection to compulsive disease. A most preferred embodiment is to detect predisposition to alcoholism, particularly because said allele has been found to be present in a majority of clinically diagnosed alcoholics. The human D.2 receptor gene A1 allele is most preferably detected in said sample.

- U. S. Patent Number: 5550343     Date of Issue: March 19, 1996

ALLELIC ASSOCIATION OF THE HUMAN DOPAMINE(D2) RECEPTOR GENE IN COMPULSIVE DISORDERS
In an important embodiment, the present invention concerns a method for detecting compulsive disorder susceptibility of a human. The method comprises initially obtaining a DNA sample of said human and then determining the presence or absence of a particular human D2 receptor gene allele in said sample. Detection of said allele in the sample is indicative of susceptibility to compulsive disorder. A most preferred embodiment is to detect a susceptibility to alcoholism and cocaine dependence, particularly because said allele has been found to be present in a majority of clinically diagnosed alcoholics and cocaine users. The human D2 receptor gene A1 and B1 alleles are most preferably detected in said sample.

- U. S. Patent Number: 5550021     Date of Issue: August 27, 1996

ALLELIC DIAGNOSIS OF SUSCEPTIBILITY TO COMPULSIVE DISORDER
In an important embodiment, the present invention concerns a method for diagnosing and detecting compulsive disorder susceptibility of an individual. The method comprises initially obtaining a DNA sample of said individual and then determining the presence or absence of particular human D2 receptor gene alleles in said sample. Detection of said alleles in the sample are indicative of predilection to compulsive disorder. A most preferred embodiment is to detect predisposition to impulsive, addictive, and compulsive disorders such as, but not limited to, alcoholism, obesity, smoking, polysubstance abuse and drug addiction, particularly because said alleles have been found to be present in a majority of individuals clinically diagnosed with these compulsive disorders. The human D2 receptor gene A1, B1, and In6-Ex7 haplotype I alleles are most preferably detected in said sample.

Patents Issued throughout Europe and Pending in Canada and Japan:

ALLELIC ASSOCIATION OF THE HUMAN DOPAMINE (D2) RECEPTOR GENE IN COMPULSIVE DISORDERS SUCH AS ALCOHOLISM
The present invention concerns a method for diagnosing compulsive disease predisposition of an individual. The method comprises initially obtaining a DNA sample of said individual and then determining the presence or absence of a particular human D2 receptor gene allele in said sample. Detection of said allele in the sample is indicative of predilection to compulsive disease. A most preferred embodiment is to detect predisposition to alcoholism, particularly because said allele has been found to be present in a majority of clinically diagnosed alcoholics. The human D2 receptor gene A1 allele is most preferably detected in said sample.

RDS Genetic Treatment

- U. S. Patent Number: 5189064     Date of Issue: February 23, 1993

TREATMENT OF COCAINE ADDICTION
Cocaine addiction is treated by administration of an endorphinase or enkephalinase inhibitor, and optionally, a dopamine precursor, or a serotonin precursor, a GABA precursor, or an endorphin or enkephalin releaser. These components promote restoration of normal neurotransmitter function and are non-addictive. Use of the dopamine precursors L-phenylalanine or L-tyrosine, the enkephalinase inhibitor D-phenylalanine and/or the serotonin precursor L-tryptophan is especially preferred (see patent opinion letters and infringement judgement).

- U. S. Patent Number: 4761429     Date of Issue: August 02, 1988

ENKEPHALINASE AND ENDORPHI�NASE INHIBITORS AS ANTI-CRAVING COMPOSITIONS
A new class of anti-craving compositions is provided by substances which inhibit breakdown of endogenous substances such as enkephalins and/or endorphins. An anti-alcohol craving effect is observed with an enkephalin breakdown inhibitor. Specifically, D-phenylalanine, DL-phenyl�alanine, D-leucine, DL-leucine, and hydrocinnamic acid, each an enkephalin breakdown inhibitor, significantly lowered alcohol intake in animals and humans. The anti-alcohol desire effect is observed in animals genetically prone to choose alcohol over water solutions.

- U.S. Patent Application     Application Date: April 29, 1998

ALLELIC POLYGENE DIAGNOSIS OF REWARD DEFICIENCY SYNDROME AND TREATMENT
Enhancement of attentional processing is attained by administration of an endorphin�ase inhibitor or enkephalinase inhibitor and optionally, a dopamine precursor, or a serotonin precursor, a GABA precursor, or an endorphin or enkephalinase releaser, or certain herbal compounds including rhodiola rosea extract (pharmaline) and/or huperzine. These components promote restoration of normal neurotransmitter function and the components combined enhance the release of dopamine at the nucleus accumbens and are non-addictive. Use of the dopamine precursors L-phenylalanine, or L-Tyrosine, the enkephali�nase inhibitor D-phenylalanine, and/or the serotonin precursor -hydroxytrypto�phan and a natural acetylcholenesterase inhibitor and chromium salts (i.e. picolinate, nicotinate, etc.) is especially preferred, but not limited to assist in relieving symptoms associated with brain phenylalanine deficiency.

- PCT Patent Application (45 Countries)     Application Date: April 29, 1998

ALLELIC POLYGENE DIAGNOSIS OF REWARD DEFICIENCY SYNDROME AND TREATMENT
Enhancement of attentional processing is attained by administration of an endorphin�ase inhibitor or enkephalinase inhibitor and optionally, a dopamine precursor, or a serotonin precursor, a GABA precursor, or an endorphin or enkephalinase releaser, or certain herbal compounds including Rhodiola rosea extract (Pharmaline) and/or Huperzine. These components promote restoration of normal neurotransmitter function and the components combined enhance the release of dopamine at the nucleus accumbens and are non-addictive. Use of the dopamine precursors L-phenylalanine, or L-Tyrosine, the enkephali�nase inhibitor D-phenylalanine, and/or the serotonin precursor-hydroxytrypto�phan and a natural acetylcholenesterase inhibitor and chromium salts (i.e. picolinate, nicotinate, etc.) is especially preferred, but not limited to assist in relieving symptoms associated with brain phenylalanine deficiency (See Table 4). Claim 93 of this patent application, which received 100% favored patent worthy report from the PCT preliminary review, involves the combination of an opiate antagonist ( Delta, Mu. Kappa, etc antagonists) such as naltrexone and an amino -acid composition of matter comprising of an opioid metabolic blocker, neurotransmitter precursor amino -acids, any chromium salt and rhodiola rosea.

- U. S. PATENT NUMBER AWARDED To Kenneth Blum, Ph.D., OCTOBER 17TH 2000. NUMBER 6,132,724.

This is a composition of matter patent which serves as a platform technology to all products commercialized by NGI.

- U.S. Patent     Date of Patent: January 12 1999.

NEW CLASS OF ANTI-HYPERTENSIVE AGENTS INCLUDING INHIBITORS OF THE BREAKDOWN OF ENKEPHALINS AND/OR ENDORPHINS, AND COMBINATIONS OF SAID ANTI-HYPERTENSIVE AGENTS WITH OTHER ANTI-HYPERTENSIVE DRUGS AND NATURAL SUBSTANCES.
The invention involves the combination of certain inhibitors of "Endorphinas�e" or "Enkephalinas�e" or other related inhibitors of enzymes involved in the breakdown of natural opioid peptides. These inhibitors could be from a group of d-amino acids and their metabolites (i.e. d-phenylalanine, Hydrocinnamic acid, d-leucine etc.) and other precursor amino-acids, especially those which effect dopamine synthesis (i.e. l-tyrosine ) as well as herbal-based natural substances (ferrulic acid, pharmaline, huperzine, hawthorn). The addition of chromium salts (picolinate, nicotinate & polynicotinate etc.) to promote a reduced risk for diabetes, reduced cholesterol, and reduced blood pressure will be most beneficial. Other important nutrients include Co-enzyme Q and Pycnogenol and d-Ribose. The combination of d-amino acids or other similar inhibitors of opioid peptidyl degradation with known anti-hypertensive agents is also considered .

- U.S. Patent     Date Filed August , 2000

A DIAGNOSTIC & TREATMENT KIT FOR REWARD DEFICIENCY SYNDROME
This patent describes the use of a kit which includes a buccal swab, an RDS scale, and a neutraceutical with or without Naltrexone. The invention also claims the use of intravenous amino -acids as a therapeutic modality.

The kit is to prevent or treat the onset of RDS and related behaviors.

There are also a number of recent US disclosures involving multiple formulae to treat RDS and related behaviors, anti-inflammatory , immune boosters and diabetes and insulin resistance.

 
 

 

Search Engine Optimization Company